# **Open Access**

# Identification of a *RAD51B* enhancer variant for susceptibility and progression to glioma



Liming Huang<sup>1\*†</sup>, Wenshen Xu<sup>2,3†</sup>, Danfang Yan<sup>4</sup>, Xi Shi<sup>5</sup>, Shu Zhang<sup>5</sup>, Meiqin Chen<sup>1</sup> and Lian Dai<sup>6\*</sup>

# Abstract

**Background** RAD51B plays a significant role in homologous recombination-mediated repair of DNA double-strand breaks. Many enhancer variants are involved in cancer development and progression. However, the significance of enhancer variants of *RAD51B* in glioma susceptibility and progression remains unclear.

**Methods** A case–control study consisting of 1056 individuals was conducted to evaluate the associations of enhancer variants of *RAD51B* with glioma susceptibility and progression. Sequenom MassARRAY technology was used for genotyping. The function of enhancer variants was explored by biochemical assays.

**Results** A significantly decreased risk of glioma was associated with rs6573816 GC genotype compared with rs6573816 GG genotype (OR = 0.66, 95% CI 0.45–0.97; P = 0.034). Multivariable Cox regression revealed that rs6573816 was significantly associated with glioma progression in a sex-dependent manner. Worse PFS was found in the male patients with high grade glioma carrying rs6573816 GC or CC genotype (HR = 2.28, 95% CI 1.14–4.57; P = 0.020). The rs6573816 C allele repressed enhancer activity by affecting transcription factor POU2F1 binding, which resulted in lower expression of *RAD51B*. Remarkably attenuated expression of *RAD51B* was observed following *POU2F1* knockdown. Consistently, positive correlation between the expression of *POU2F1* and *RAD51B* was found in lymphoblastic cells and glioma tissues.

**Conclusions** These results indicate that an enhancer variant of *RAD51B* rs6573816 influences enhancer activity by changing a POU2F1 binding site and confers susceptibility and progression to glioma.

Keywords Glioma, RAD51B, Enhancer, Genetic variation, Susceptibility, Progression

 $^{\dagger}\mbox{Liming}$  Huang and Wenshen Xu contributed equally and should be considered co-first authors.

# \*Correspondence:

Liming Huang huangliming331@163.com; huangliming331@fjtcm.edu.cn Lian Dai

- dailianarticle@163.com
- <sup>1</sup> Department of Oncology, The Affiliated People's Hospital, Fujian
- University of Traditional Chinese Medicine, #602 Bayiqizhong Road, Fuzhou 350004, China
- <sup>2</sup> Department of Laboratory Medicine, The First Affiliated Hospital, Fujian Medical University, Fuzhou 350005, China
- <sup>3</sup> Fujian Key Laboratory of Laboratory Medicine, The First Affiliated
- Hospital, Fujian Medical University, Fuzhou 350005, China
- <sup>4</sup> Department of Radiation Oncology, The First Affiliated Hospital, College
- of Medicine, Zhejiang University, Hangzhou 310003, China
- <sup>5</sup> Department of Medical Oncology, The First Affiliated Hospital, Fujian Medical University, Fuzhou 350005, China



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

<sup>6</sup> Department of Medicine, The Third Affiliated People's Hospital, Fujian University of Traditional Chinese Medicine, #363 Guobin Road, Fuzhou 350108, China

# Background

Glioma is the most common form of primary malignant intracranial tumors. Numerous epidemiologic studies have revealed some genetic and environmental risk factors for glioma. Most noteworthy, ionizing radiation has been firmly established as an unequivocal environmental risk factor for glioma [1]. Ionizing radiation can induce various types of DNA damage, such as DNA single- and double-strand breaks. Progressive accumulation of DNA damage is an important mechanism in glioma carcinogenesis. On the other hand, as the mainstay in the treatment of glioma, radio- and chemotherapy exhibit their anticancer activity mainly via promoting DNA damages.

DNA double-strand breaks are the most perilous and lethal type of DNA damage, requiring timely repair [2]. Cells are estimated to suffer up to 50 DNA double-strand break events per day. Homologous recombination repair is one of the most important pathways to repair DNA double-strand breaks [2]. RAD51 protein family plays a critical role in homologous recombination-mediated DNA double-strand breaks repair. As a member of the RAD51 protein family, RAD51B can form a complex with other RAD51 paralogs, and then promote RAD51mediated homologous DNA pairing and strand exchange [3]. Accumulative evidence has revealed that abnormal RAD51B is involved in carcinogenesis. Overexpression of RAD51B was found to promote cell proliferation and aneuploidy in gastric cancer [4]. Moreover, a high prevalence of RAD51B copy number alterations was observed in uterine leiomyosarcoma [5]. In addition, as an important DNA repair gene, RAD51B also has been identified to be associated with therapy resistance and prognosis of several cancers [4, 6, 7].

Enhancers are an important regulatory element dispersed widely throughout the human genome. Proper enhancer activity is essential for coordinated dynamic gene transcription. Accumulative evidence suggests that inappropriate enhancer activity is involved in cancer development and progression [8, 9]. Several cancer susceptibility variants identified by genome-wide association studies were found to affect regulatory activity of enhancers [8]. Significantly, a genome-wide analysis of somatic noncoding mutation patterns in cancer has revealed that *RAD51B* harbors frequent noncoding mutations in promoter and enhancer regions [10]. Therefore, it is worthwhile to evaluate the role of enhancer variants of *RAD51B* in glioma development and progression.

In this study, we conducted a case–control study consisting of 402 glioma patients and 654 controls to investigate whether enhancer variants of *RAD51B* confer susceptibility and progression to glioma. Then, the functional relevance of enhancer variants of *RAD51B* was explored.

# Methods

# Study subjects

This study comprised 402 glioma patients and 654 cancer-free population controls. Patients were recruited from Fujian, Zhejiang, and surrounding provinces between January 2010 and July 2016. Controls were cancer-free individuals recruited in the same time period. All subjects were unrelated Southern Han Chinese (CHS). For each patient, the pathologic diagnosis of glioma was confirmed according to the 2007 WHO classification of tumors of the central nervous system at initial diagnosis and reclassified according to the 2016 WHO classification of tumors of the central nervous system in this study [11, 12]. The progression-free survival (PFS) time of glioma patients was calculated as the time between date of initial treatment and date of progressive disease or death. The patients lost to follow-up or without progression were censored at the time of the last tumor evaluation. The date of last follow-up was February 3, 2020. The clinical characteristics of study subjects are presented in Additional file 1. Written informed consent was obtained from all subjects and this study was approved by the Institutional Review Board of the First Affiliated Hospital, Fujian Medical University.

# Selection of candidate genetic variations

VISTA Enhancer Browser (https://enhancer.lbl.gov/) was used to explore potential enhancers of *RAD51B* [13]. UCSC Genome Browser (http://www.genome.ucsc.edu/, GRCh37/hg19) was used to display the details of regions of interest [14]. The ENCODE regulation tracks show the H3K4Me1, H3K4Me3, and H3K27Ac histone modifications which are suggestive of enhancer and promoter. The DNase Clusters track displays regions where the chromatin is hypersensitive to DNase enzyme [15]. The ORegAnno track displays literature-curated regulatory elements [16]. In this study, we picked out the common enhancer variants with minor allelic frequency (MAF) of  $\geq$  10% in CHS population to assess the linkage disequilibrium (LD) status using Haploview v4.2 software. Then, tag variants were selected for genotyping.

# Genotype analysis

Genomic DNA samples were isolated from peripheral blood lymphocytes using Tiangen TIANamp Genomic DNA kit (Tiangen Biotech., Beijing, China). Genotype analysis was performed by Sequenom MassARRAY iPLEX platform (Sequenom Inc., San Diego, CA, USA). The representative clustering graph was presented in Additional file 2. We implemented several measures to control genotyping quality, including (1) genotyping was carried out without knowledge of the case/control status, (2) each assay plate contained both case and control samples, (3) each assay plate contained both positive and negative controls.

# Luciferase reporter gene assays

A 2759-bp DNA fragment corresponding to the enhancer hs1474 of *RAD51B* was subcloned into the pGL3-promoter vector (Promega, Madison, WI, USA). The resultant construct containing rs6573816 G allele was designated as P-G, while the other one containing rs6573816 C allele was designated as P-C. The constructs were sequenced to confirm their authenticity. Then, the constructs P-G, P-C, or the empty pGL3-promoter vector was co-electrotransfected with pRL-TK (Promega) into U251 cells, respectively. The luciferase activity was detected with a Dual-Luciferase Reporter Assay System (Promega). The U251 cells obtained from X–Y Biotechnology Corporation (Shanghai, China) were authenticated by DNA finger printing analysis and tested for mycoplasma contamination.

# Chromatin immunoprecipitation assays

Web application AliBaba2.1 (http://gene-regulation.com/ pub/programs/alibaba2/index.html) was used to explore the transcription factor binding to rs6573816 locus with minimum matrix conservation of 70%. Then, chromatin immunoprecipitation (ChIP) assays were performed in U251 cells to verify the prediction. Cells were crosslinked in 1% formaldehyde followed by lysing and sonicating. Immunoprecipitation was performed using a BersinBio ChIP Kit (BersinBio Biotech., Guangzhou, Guangdong, China) and antibodies against predicted transcription factor POU2F1 or nonspecific rabbit IgG (Proteintech., Rosemont, IL, USA). Purified DNA was analyzed by PCR. Furthermore, to rule out nonspecific antibody-DNA interaction, we also analyzed the randomly selected region of GAPDH promoter by PCR. The PCR primers are presented in Additional file 3.

Subgroup		OR (95% CI)
Sex Male Female	<b>-</b>	0.73 (0.46–1.17) 0.60 (0.33–1.10)
Age (year) ≤50 >50	; ;	0.70 (0.41–1.17) 0.66 (0.38–1.14)
WHO grade I III IV Low grade High grade		0.50 (0.09–2.87) 0.50 (0.25–1.00) 0.64 (0.31–1.33) 0.82 (0.50–1.35) 0.49 (0.25–0.95) 0.75 (0.49–1.15)
IDH status IDH wildtype IDH mutant IDH NOS Overall	 	0.44 (0.20–0.98) 0.81 (0.37–1.81) 0.75 (0.49–1.15) 0.68 (0.47–0.99)
0		1 2

**Fig. 1** Subgroup analyses for rs6573816 based on sex, age, WHO grade, and *IDH* mutation status in a dominant model. Central black dots indicate ORs. Horizontal lines represent 95% Cls

## siRNA mediated gene knockdown

We designed three silencing RNAs (siRNAs) to knockdown *POU2F1* expression. The *POU2F1* siRNAs and control siRNA were transfected into U251 cells respectively. The cells were collected after 48 h. Trizol (Life Technologies, Carlsbad, CA, USA) was used to isolate total RNA. RT-qPCR was used for analyses of *POU2F1* and *RAD51B* mRNA levels with TB Green Premix Ex Taq (Takara Bio., Shiga, Japan). The siRNAs and primers are summarized in Additional file 3. Western blot analyses were performed with primary antibodies against POU2F1 or RAD51B (Proteintech.) to measure protein levels. GAPDH was applied as a reference.

Table 1 Genotype frequencies of rs6573816 and its association with g	glioma risk
--	-------------

Genotypeª	Patients (n = 402) No. (%)	Controls (n = 654) No. (%)	OR <sup>b</sup> (95%CI)	Р
GG	350 (87.94)	540 (83.20)	1.00 (reference)	
GC	45 (11.31)	103 (15.87)	0.66 (0.45–0.97)	0.034
CC	3 (0.75)	6 (0.93)	1.03 (0.25-4.22)	0.964
GC+CC vs. GG			0.68 (0.47-0.99)	0.041

OR odds ratios, Cl confidence interval

<sup>a</sup> Some samples failed to genotype

 $^{\rm b}$  Data were calculated by logistic regression with adjustment for age and sex



Fig. 2 Kaplan–Meier estimates of PFS of the male glioma patients according to rs6573816 genotypes. a All male patients. b The male patients with high grade glioma. c The male patients underwent radiotherapy

Table 2 Multivariate analysis of rs6573816 on glioma progression in the different groups of male patients

Subgroup	Genotype	Median PFS (95%Cl, months)	HR <sup>a</sup> (95% CI)	Р
All	GG	30 (19–48)	1.00 (reference)	
	GC	12 (7–59)	1.74 (0.90–3.34)	0.097
	CC	5 (NC)	4.80 (0.61–37.50)	0.135
	GC+CC	11 (7–59)	1.83 (0.97–3.45)	0.061
High grade glioma	GG	14 (11–19)	1.00 (reference)	
	GC	11 (4–17)	2.15 (1.05–4.40)	0.036
	CC	5 (NC)	8.04 (0.96–67.13)	0.054
	GC+CC	10 (4–12)	2.28 (1.14–4.57)	0.020
Underwent radiotherapy	GG	29 (19–48)	1.00 (reference)	
	GC	11 (6–59)	1.48 (0.68–3.21)	0.318
	CC	5 (NC)	8.76 (1.01–76.11)	0.049
	GC+CC	11 (5–59)	1.63 (0.78–3.43)	0.200

PFS progression-free survival, CI confidence interval, HR hazard ratio

<sup>a</sup> Data were calculated by multivariate Cox regression with adjustment for age, WHO grade, resection extent, radio- and chemotherapy when appropriate

# Correlation analysis between rs6573816 and *RAD51B* expression

Gene Expression Omnibus (GEO, http://www.ncbi.nlm. nih.gov/geo/) was used to extract the expression data of *RAD51B* [17]. The dataset with GEO accession number GSE6536, which includes whole-genome gene expression data of the lymphoblastic cell lines from HapMap individuals, was used in this study [18]. The target ID of *RAD51B* is GI\_19924114-I. And the gene expression data normalized by a median normalization method across all HapMap individuals was extracted. The genotype data of rs6573816 for the HapMap individuals was extracted from the International HapMap Project [19].

# Correlation analysis between the expression of *POU2F1* and *RAD51B*

The normalized gene expression data of *POU2F1* and *RAD51B* measured in the lymphoblastic cell lines was

extracted as described in the previous section. The target ID of *POU2F1* is GI\_42476163-S. Meanwhile, the gene expression data from glioma tissues was extracted from the Chinese Glioma Genome Atlas (CGGA) database (http://www.cgga.org.cn/index.jsp) [20]. In this study, we used the dataset mRNAseq\_693 which includes mRNA sequencing data from 693 glioma tissues.

#### Statistical analysis

The associations between genotypes and glioma risk were estimated by logistic regression models. PFS curve was plotted using the Kaplan–Meier method, followed by logrank test. Multivariable Cox regression with adjustment for sex, age, WHO grade, resection extent, radio- and chemotherapy, when appropriate, was performed to calculate hazard ratios (HRs) and 95% confidence intervals (CIs). The differences in luciferase reporter gene expression and gene expression levels were examined by a



**Fig. 3** a The functional effect of rs6573816 on *RAD51B* expression in population (n = 270). b Reporter gene assays with constructs containing the potential enhancer (hs1474) with rs6573816 G allele (P-G) or C allele (P-C) in U251 cells. Columns represent means; Bars indicate SE

t-test. Pearson correlation was performed to analyze the expression correlation of *POU2F1* and *RAD51B*. Statistical analysis was carried out using Statistic Analysis System software (version 9.4, SAS Institute, Cary, NC, USA). The *P* value of < 0.05 was used as the criterion of statistical significance.

# Results

Four potential enhancers of *RAD51B* were identified by VISTA Enhancer Browser (hs1474, hs1392, hs1616, and hs1688). In silico analysis revealed that the degrees of enrichment of H3K4Me1 and H3K27Ac histone modifications in hs1474 are much higher than others (Additional file 4). More literature-curated regulatory elements were also found in hs1474 by ORegAnno track. Moreover, there are several DNaseI hypersensitive sites locating in hs1474. Therefore, we just picked out the common variants of hs1474 for further analyses. After linkage disequilibrium analysis, a common variant rs6573816 whose MAF is of 10% in CHS population was identified as tag variant for genotyping.

The results from the genotyping assay were shown in Table 1. The genotype frequencies of rs6573816 were 87.94% (GG genotype), 11.31% (GC genotype), 0.75% (CC genotype) in cases and 83.20% (GG), 15.87% (GC), and 0.93% (CC) in controls which were in agreement with that expected under Hardy-Weinberg equilibrium. Logistic regression showed that rs6573816 GC genotype was associated with a significantly decreased risk of glioma (odds ratio [OR] = 0.66, 95% CI 0.45–0.97; *P*=0.034) compared with rs6573816 GG genotype. No significant association was found for rs6573816 CC genotype (P=0.964), which might be due to the low frequency of rs6573816 CC genotype. When rs6573816 GC and CC genotypes were pooled for analysis, a significantly decreased risk of glioma was also found (OR = 0.68, 95% CI 0.47–0.99; P = 0.041).

Then, subgroup analyses for rs6573816 based on sex, age, WHO grade, and *IDH* mutation status were performed in a dominant model (Fig. 1). Downward trend in glioma risk of subjects with rs6573816 GC or CC genotype was observed in all subgroups. In low grade glioma and *IDH* wildtype glioma subgroups, significantly reduced risk of glioma was observed with ORs of 0.49 (95% CI 0.25–0.95; P=0.034) and 0.44 (95% CI 0.20–0.98; P=0.046) respectively. The relatively small sample size within a given stratum may be part of the reason why there was no significant association in other subgroups.

The impact of clinical factors and rs6573816 on glioma progression was analyzed by log-rank test. The results indicated that age, WHO grade, and resection extent were significantly associated with glioma progression (Additional file 5). PFS was significantly improved in patients aged  $\leq 50$  years (P < 0.001), with lower grade glioma (P < 0.001), and underwent a more extensive resection (P = 0.002). The sex, radiotherapy, chemotherapy, and rs6573816 were not found to correlate with glioma progression in the whole group of patients (P > 0.05). Further subgroup analyses were employed to assess the impact of rs6573816 on glioma progression in the different groups of patients. As shown in Additional file 6 and Fig. 2a, rs6573816 was found to be significantly associated with PFS in the male glioma patients by log-rank test (P = 0.019). Multivariable Cox regression revealed that the association between rs6573816 and PFS in the male glioma patients just reach marginal significance level in a dominant model (Table 2, HR = 1.83, 95% CI 0.97-3.45; P = 0.061). However, further analyses indicated that rs6573816 was significantly associated with PFS in the male patients



**Fig. 4** a rs6573816 resides within POU2F1 DNA-binding motif. **b** ChIP assays in U251 cells with rs6573816 GG genotype. The presence of POU2F1-binding *RAD51B* enhancer hs1474 was verified by PCR. **c** Depletion of *POU2F1* by RNAi attenuates the mRNA levels of *RAD51B*. Columns represent means; Bars indicate SE. \*\*\* P<0.001. **d** Knockdown of *POU2F1* by RNAi downregulates the protein levels of *RAD51B* 

with high grade glioma (Fig. 2b, P=0.030) or underwent radiotherapy (Fig. 2c, P=0.002). Multivariable Cox regression revealed that subjects with rs6573816 GC genotype had a worse PFS in the male patients with high grade glioma (Table 2, HR=2.15, 95% CI 1.05–4.40; P=0.036). When rs6573816 GC and CC genotypes were pooled for analysis, a worse PFS was also found (HR=2.28, 95% CI 1.14–4.57; P=0.020). In the male patients underwent radiotherapy, subjects with rs6573816 CC genotype had a worse PFS (HR=8.76, 95% CI 1.01–76.11; P=0.049). Interestingly, no significant association was found in the female glioma patients (Additional file 7).

We further investigated whether rs6573816 has a functional effect on *RAD51B* expression in population. As shown in Fig. 3a, we found that subjects with rs6573816 GC genotype had lower expression levels of *RAD51B* than those with GG genotype (P=0.029). To examine whether rs6573816 interferes with the regulatory activity of enhancer hs1474 in cell line, luciferase reporter gene assays were performed with constructs P-G and P-C encompassing hs1474 with rs6573816 G or C allele, respectively. As shown in Fig. 3b, both constructs P-G and P-C containing enhancer hs1474 drove significantly higher luciferase activity than the empty pGL3-promoter plasmid (both P<0.001). Besides, significantly increased luciferase activity was observed for P-G compared with P-C (P<0.001).

As shown in Fig. 4a, rs6573816 was predicted to be within the binding site of transcription factor POU2F1. In order to verify the prediction in cell line, we carried out ChIP assays in U251 cells with rs6573816 GG geno-type. As shown in Fig. 4b, POU2F1 antibody immunoprecipitated rs6573816 locus specifically but not nonspecific region of *GAPDH* promoter. The results revealed the existence of POU2F1 binding to rs6573816 locus in cell line.

Then, siRNAs were designed to silence *POU2F1* expression to evaluate the effect of POU2F1 on *RAD51B* expression. The interference efficiency of



**Fig. 5** Correlation between the expression of *POU2F1* and *RAD51B* in lymphoblastic cells and glioma tissues. **a** Lymphoblastic cells from HapMap individuals (n = 270). **b** Glioma tissues from CGGA database (n = 693)

three siRNAs was shown in Additional file 8. The siRNA-1 and siRNA-3 with higher interference efficiency were chosen for further analysis. As shown in Fig. 4c, the siRNA-1 and siRNA-3 significantly reduced the relative mRNA levels of *POU2F1* (both P < 0.001). Follow by, the relative mRNA levels of *RAD51B* were also significantly decreased (both P < 0.001). Consistent with the mRNA trend, the siRNA-1 and siRNA-3 significantly downregulated the protein expression of POU2F1, which was accompanied by attenuated protein expression of RAD51B (Fig. 4d).

We further explored the relationship between the expression of *POU2F1* and *RAD51B* in lymphoblastic cells, positive correlation was observed between the expression of *POU2F1* and *RAD51B*, with Pearson r value being 0.139 (P=0.023, Fig. 5a). Consistently, positive

correlation was also observed in glioma tissues, with Pearson r value being 0.080 (P = 0.036, Fig. 5b).

# Discussion

In the present study, an enhancer variant of *RAD51B* rs6573816 was found to be significantly associated with glioma susceptibility and progression in a sex-dependent manner. In addition, we found that rs6573816 C allele might downregulate *RAD51B* expression by affecting transcription factor POU2F1 binding.

The DNA double-strand break is a particularly deleterious form of DNA damage induced by ionizing radiation [2]. Unrepaired and misrepaired DNA double-strand breaks contribute to the genomic instability, and then lead to cancer. Therefore, it is not surprising that the imbalance of DNA double-strand break repair pathways results in accumulation of deleterious DNA damage and is associated with carcinogenesis. Previous studies have revealed that genetic lesions disrupting DNA doublestrand break repair pathways are involved in carcinogenesis [21]. RAD51 protein family is essential for DNA double-strand break repair by homologous recombination. In the present study, we found that an enhancer variant of RAD51B rs6573816 was associated with glioma susceptibility, which implies a significant role of RAD51B in glioma development. Of note, the rs6573816 C allele driving lower expression of RAD51B was found to decrease the risk of glioma significantly. Logically, our findings indicate that overexpression of RAD51B might be a risk factor for glioma. Interestingly, an intron variant of RAD51B rs2189517 has been demonstrated to be associated with rectal cancer risk [22]. We investigated the functional effect of rs2189517 on RAD51B expression in lymphoblastic cells from HapMap individuals as mentioned above. In consistent with our results, the risk rs2189517 G allele was significantly associated with higher expression of RAD51B (Additional file 9). Furthermore, upregulated expression of RAD51B was observed in gastric precancer and cancer tissues. It has been revealed that overexpression of RAD51B leads to enhanced cell proliferation and elevated genetic instability [4]. Likewise, increased protein level of RAD51, another member of the RAD51 protein family, has been observed in various cancers [23]. In myeloma and Barrett's esophageal adenocarcinoma, overexpression of RAD51 was found to enhance homologous recombination activity and then lead to pathological recombination events [24, 25]. These results suggest that the precisely regulated activity of homologous recombination is critical for the maintenance of genome stability. While, overexpression of *RAD51B* might function as a susceptibility factor for glioma.

DNA repair is considered as a double-edged sword because of its diversified roles in cancer initiation, progression, and therapy. For instance, ERCC1 variant rs2298881 G allele increasing the risk of lung cancer development is associated with better prognosis [26]. In the present study, we also found that the rs6573816 C allele, which was identified as a protective allele for glioma development and drove lower expression of RAD51B, increased the risk of glioma progression in a sex-dependent manner. These results indicate that low expression of RAD51B might be an adverse prognostic factor for glioma. Consistently, high expression of RAD51B has been found to be associated with a favorable prognosis for breast cancer and lung cancer [6, 7]. Previous study has demonstrated that overexpression of RAD51B can induce cell apoptosis after irradiation [27]. On the other hand, sex differences in glioma in terms of incidence, prognosis, pathophysiology, and cancer biology have been widespread concern [28]. Our previous studies also found that hematologic and serum biomarkers are sex-dependently associated with glioma grade and prognosis [29, 30]. This study provides additional evidence that there may be sex-specific effects of genetic variations on glioma progression.

# Conclusions

In conclusion, an enhancer variant of *RAD51B* rs6573816 was identified as a novel susceptibility and progression locus for glioma. And subjects with rs6573816 GC or CC genotype experienced a downward trend in glioma risk in all subgroups. While the rs6573816 C allele increased the risk of disease progression in a sex-dependent manner. The rs6573816 C allele was found to downregulate the expression of *RAD51B* by disrupting a POU2F1 binding site. These results indicate that an enhancer variant of *RAD51B* rs6573816 influences enhancer activity by changing a POU2F1 binding site and confers susceptibility and progression to glioma.

#### Abbreviations

CHS	Southern Han Chinese
PFS	Progression-free survival
MAF	Minor allelic frequency
LD	Linkage disequilibrium
ChIP	Chromatin immunoprecipitation
siRNA	Silencing RNA
GEO	Gene Expression Omnibus
CGGA	Chinese Glioma Genome Atlas
HR	Hazard ratio
CI	Confidence interval
OR	Odds ratios

# Supplementary Information

The online version contains supplementary material available at https://doi. org/10.1186/s12935-023-03100-8.

Additional file 1: Table S1. Clinical characteristics of glioma patients and controls.

Additional file 2: Figure S1. The representative clustering graph of rs6573816 genotyping.

Additional file 3: Table S2. Oligonucleotides for ChIP-PCR, RNAi, and RT-qPCR.

Additional file 4: Figure S2. In silico analysis of four potential enhancers of *RAD51B*.

Additional file 5: Table S3. Univariate analysis of clinical factors and rs6573816 on glioma progression.

Additional file 6: Table S4. Univariate subgroup analysis of rs6573816 on glioma progression.

Additional file 7: Figure S3. Kaplan–Meier estimates of PFS of the female glioma patients according to rs6573816 genotypes. (A) All female patients. (B) The female patients with high grade glioma. (C) The female patients underwent radiotherapy.

Additional file 8: Figure S4. Interference efficiency of the candidate siRNA oligonucleotides for *POU2F1*. (A) The mRNA levels of *POU2F1* after transfecting siRNAs. Columns represent means; Bars indicate SE. (B) The protein levels of *POU2F1* after transfecting siRNAs.

Additional file 9: Figure S5. The functional effect of rs2189517 on RAD51B expression in population (n = 270).

#### Acknowledgements

The authors wish to thank pathologist Li Zhang for her assistance in reclassifying the pathologic diagnosis according to the 2016 WHO classification of tumors of the central nervous system. We also thank all the study participants and students who participated in this work.

#### Author contributions

LMH and LD conceived and designed the study; LMH, WSX, DFY, XS, SZ and MQC collected subjects and clinical data; LMH, WSX and DFY performed experiments; LMH, WSX and LD analyzed the data and participated in the discussion; LMH and LD wrote and revised the manuscript. All authors read and approved the final manuscript.

#### Funding

This work was supported by grants from the National Natural Science Foundation of China (Grant no. 81973118).

#### Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

### Declarations

#### Ethics approval and consent to participate

The use of human blood sample and the protocol in this study were strictly comply with the criterions of the Declaration of Helsinki and were approved by the Institutional Review Board of the First Affiliated Hospital, Fujian Medical University, Fujian, China. Written informed consent was received from each participant.

#### **Consent for publication**

Not applicable.

#### **Competing interests**

The authors declare that they have no competing interests.

Received: 26 February 2023 Accepted: 14 October 2023 Published online: 19 October 2023

### References

- 1. Ostrom QT, Bauchet L, Davis FG, Deltour I, Fisher JL, Langer CE, et al. The epidemiology of glioma in adults: a "state of the science" review. Neuro Oncol. 2014;16:896–913.
- Provasek VE, Mitra J, Malojirao VH, Hegde ML. DNA double-strand breaks as pathogenic lesions in neurological disorders. Int J Mol Sci. 2022;23:4653.
- Sigurdsson S, Van Komen S, Bussen W, Schild D, Albala JS, Sung P. Mediator function of the human Rad51B-Rad51C complex in Rad51/RPA-catalyzed DNA strand exchange. Genes Dev. 2001;15:3308–18.
- Cheng Y, Yang B, Xi Y, Chen X. RAD51B as a potential biomarker for early detection and poor prognostic evaluation contributes to tumorigenesis of gastric cancer. Tumour Biol. 2016;37:14969–78.
- Ciccarone F, Bruno M, De Paolis E, Piermattei A, De Bonis M, Lorusso D, et al. Role of homologous recombination repair (HRR) genes in uterine leiomyosarcomas: a retrospective analysis. Cancers (Basel). 2022;14:1934.
- Shi Y, Shen M, Xu M, Tao M, Chen K, Zhu Q. Comprehensive analysis of the expression and prognosis for RAD51 family in human breast cancer. Int J Gen Med. 2022;15:4925–36.
- Wu M, Sheng Z, Jiang L, Liu Z, Bi Y, Shen Y. Overexpression of RAD51B predicts a preferable prognosis for non-small cell lung cancer patients. Oncotarget. 2017;8:91471–80.
- Herz HM. Enhancer deregulation in cancer and other diseases. BioEssays. 2016;38:1003–15.
- Wang Y, Hao DP, Li JJ, Wang L, Di LJ. Genome-wide methylome and chromatin interactome identify abnormal enhancer to be risk factor of breast cancer. Oncotarget. 2017;8:44705–19.
- Dietlein F, Wang AB, Fagre C, Tang A, Besselink NJM, Cuppen E, et al. Genome-wide analysis of somatic noncoding mutation patterns in cancer. Science. 2022;376:eabg5601.
- Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114:97–109.
- Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131:803–20.
- Visel A, Minovitsky S, Dubchak I, Pennacchio LA. VISTA enhancer browsera database of tissue-specific human enhancers. Nucleic Acids Res. 2007;35:D88-92.
- Kent WJ, Sugnet CW, Furey TS, Roskin KM, Pringle TH, Zahler AM, et al. The human genome browser at UCSC. Genome Res. 2002;12:996–1006.
- ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human genome. Nature. 2012;489:57–74.
- Lesurf R, Cotto KC, Wang G, Griffith M, Kasaian K, Jones SJ, et al. ORegAnno 3.0: a community-driven resource for curated regulatory annotation. Nucleic Acids Res. 2016;44:D126–32.
- Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, et al. NCBI GEO: archive for functional genomics data sets–update. Nucleic Acids Res. 2013;41:D991–5.
- Stranger BE, Nica AC, Forrest MS, Dimas A, Bird CP, Beazley C, et al. Population genomics of human gene expression. Nat Genet. 2007;39:1217–24.
- International HapMap Consortium. The International HapMap Project. Nature. 2003;426:789–96.
- Zhao Z, Zhang KN, Wang Q, Li G, Zeng F, Zhang Y, et al. Chinese Glioma Genome Atlas (CGGA): a comprehensive resource with functional genomic data from chinese glioma patients. Genomics Proteom Bioinform. 2021;19:1–12.
- 21. Aparicio T, Baer R, Gautier J. DNA double-strand break repair pathway choice and cancer. DNA Repair (Amst). 2014;19:169–75.
- Pardini B, Corrado A, Paolicchi E, Cugliari G, Berndt SI, Bezieau S, et al. DNA repair and cancer in colon and rectum: novel players in genetic susceptibility. Int J Cancer. 2020;146:363–72.
- Nagathihalli NS, Nagaraju G. RAD51 as a potential biomarker and therapeutic target for pancreatic cancer. Biochim Biophys Acta. 2011;1816:209–18.

- Shammas MA, Shmookler Reis RJ, Koley H, Batchu RB, Li C, Munshi NC. Dysfunctional homologous recombination mediates genomic instability and progression in myeloma. Blood. 2009;113:2290–7.
- Pal J, Bertheau R, Buon L, Qazi A, Batchu RB, Bandyopadhyay S, et al. Genomic evolution in Barrett's adenocarcinoma cells: critical roles of elevated hsRAD51, homologous recombination and Alu sequences in the genome. Oncogene. 2011;30:3585–98.
- Yu D, Zhang X, Liu J, Yuan P, Tan W, Guo Y, et al. Characterization of functional excision repair cross-complementation group 1 variants and their association with lung cancer risk and prognosis. Clin Cancer Res. 2008;14:2878–86.
- Havre PA, Rice MC, Noe M, Kmiec EB. The human REC2/RAD51B gene acts as a DNA damage sensor by inducing G1 delay and hypersensitivity to ultraviolet irradiation. Cancer Res. 1998;58:4733–9.
- Carrano A, Juarez JJ, Incontri D, Ibarra A, Guerrero Cazares H. Sex-specific differences in glioblastoma. Cells. 2021;10:1783.
- Xu W, Huang L, Xie B, Yang B. Serum microRNA-4297 is a sex-specific predictive biomarker of glioma grade and prognosis. Front Neurol. 2022;13: 888221.
- Xu W, Wang D, Zheng X, Ou Q, Huang L. Sex-dependent association of preoperative hematologic markers with glioma grade and progression. J Neurooncol. 2018;137:279–87.

# **Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

#### Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

#### At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

